Development update
04 3월 2009 - 4:00PM
UK Regulatory
TIDMMMG
RNS Number : 2625O
Medical Marketing Int'l Group PLC
04 March 2009
Development update
4 March 2009 - Medical Marketing International Group plc ("MMI" or the
"Company") (AIM:MMG), the life sciences company focused on the development of
drugs for cancer, today announces the following update on the Company's cancer
vaccines and ruthenium chemotherapies.
Cancer vaccines
The commercial prostate cancer vaccine ("GVX 3322") has completed the
preclinical equivalence studies with the academic vaccine being used in the
current clinical trial. The positive result obtained in this study allows the
Company to continue its preparations for the commencement of a Phase II trial.
Planning for the clinical development of GVX 3322 has continued and discussions
with leading clinical oncologists are defining the key parameters for a prostate
cancer trial. It is evident that the design of this trial will depend critically
on the data from the current trial and, in particular, on the PSA-response rate
that is observed. The Company is in discussions with the University of
Southampton and Cancer Research Technology to obtain these data.
Ruthenium chemotherapies
The ruthenium compound ONCO 4417 has been investigated in a number of
pre-clinical studies to enhance our understanding of the mechanism of action by
which it kills cancer cells. These studies show that ONCO 4417 induces DNA
damage to levels comparable with that of cisplatin and suggest that the induced
DNA damage may directly or indirectly result in apoptosis (programmed cell
death). In addition, as ONCO 4417 does not appear to share cross-resistance
mechanisms with cisplatin, it is likely that damage induced by ONCO 4417 is not
resolved in the same way as that induced by cisplatin and therefore, may provide
novel cancer targets for our ruthenium compounds. A summary of this work has
been approved for a poster presentation at the American Association of Cancer
Research Annual Meeting on 18-22 April 2009 in Denver, Colorado.
We continue to focus on investigating the mechanisms responsible for repair of
ONCO 4417 induced damage and on evaluating the compound in xenograft models. The
findings will be used to target our ruthenium compounds to cancers where the
drug will have most effect and to investigate the combination of ONCO 4417 with
other drug agents. We also continue to evaluate the second generation compounds,
prepared using a targeted synthesis approach, which have now demonstrated good
in vitro efficacy across our panel of human tumour cells.
Enquiries:
+-----------------------------------------+-----------------------------------------+
| Medical Marketing International Group | |
| plc | |
+-----------------------------------------+-----------------------------------------+
| Phil Cartmell, Non-executive Chairman | Tel: +44 (0) 1223 477 677 |
| Mark Burton, Chief Technical Officer | |
| Rob Sprawson, Chief Financial Officer | |
+-----------------------------------------+-----------------------------------------+
| | |
+-----------------------------------------+-----------------------------------------+
| FinnCap | |
+-----------------------------------------+-----------------------------------------+
| Sam Smith/Charlie Cunningham | Tel: +44 (0)20 7600 1658 |
+-----------------------------------------+-----------------------------------------+
| | |
+-----------------------------------------+-----------------------------------------+
| Financial Dynamics | |
+-----------------------------------------+-----------------------------------------+
| David Yates/Emma Thompson | Tel: +44 (0)20 7831 3113 |
+-----------------------------------------+-----------------------------------------+
About MMI
Medical Marketing International Group plc ("MMI") is a life sciences company
that identifies, acquires and develops world-class compounds and technologies
for the treatment of cancer. The Company manages the preclinical and early
clinical development of drug candidates before pursuing licensing partners to
manage late-stage development. Please visit www.mmigroup.co.uk for further
information.
Notwithstanding the inclusion on this release by MMI of a website address and/or
another electronic address, MMI does not accept any notices or any other
documents or communication via its website or other electronic address. All such
notices, documents or communication shall be in hard copy format only.
Accordingly the provisions of section 333 Companies Act 2006 allowing persons to
communicate with MMI electronically shall not apply to MMI.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUUUBGWUPBGMW
Medical Mktg (LSE:MMG)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Medical Mktg (LSE:MMG)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Medical Mktg (London Stock Exchange)의 실시간 뉴스: 최근 기사 0
More Medical Mkting Int'l News Articles